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The Effect of Platelets in the Activation of Human Blood
Coagulation Factor IX by Factor XIa
By Hans Soons, Truus Janssen-Claessen, H. Coenraad Hemker, and Guido Tans
We report here the effect of activated human platelets on
the activation of human factor IX by human factor Xla.
Factor IXa formed during activation was determined via its
ability to activate bovine factor X. To increase sensitivity,
phospholipids and bovine factor VIlla were present in the
assay. The kinetic parameters of the factor IX activation
were determined in the presence of 10 mmol/L CaCI2. The
Km for factor IX was 0.30 mol/L and k, was 2.4 s.
Activated human platelets inhibited factor IX activation by
factor Xla in a dose-dependent manner. whereas unstim-
ulated platelets had no effect. Factor IX activation was
inhibited for more than 90% at a platelet concentration of
4 x 108/mL, whereas concentrations of less than 10/mL
had no influence. The inhibitory effect could be induced by
thrombin, collagen. calcium ionophore A 23i 87, and adren-
aIm. The appearance of inhibitory activity could be blocked
by the addition of the prostacyclin analogue ZK 36374 at
H UMAN FACTOR IX is a vitamin K-dependent
plasma protein that participates in the intrinsic path-
way of blood coagulation.’ It is present in plasma as a
zymogen with a molecular weight (mol wt) of 57,000 daltons
(d) at a concentration of 2.6 to 5.0 zg/mL. Human factor IX
is converted to a serine protease, factor IXa, through proteol-
ysis of two internal peptide bonds. This results in the release
of an activation peptide (1 1 ,000 d) from the internal region
of the precursor molecule. The resulting factor IXa (46,000
d) consists of a light chain (18,000 d) and heavy chain
(28,000 d) held together by a disulfide bond(s).23 Activation
of factor IX in plasma can be accomplished by factor X1a23
or by the factor VIla-tissue thromboplastin complex.5
Platelets play an important role in blood coagulation. The
platelet surface strongly promotes prothrombin and intrinsic
factor X activation.6 The activation of factor IX by factor
XIa is one of the few reactions of coagulation for which no
surface requirement is known. It has been suggested that
collagen-stimulated platelets exhibit factor XIa-like activi-
ty, which can be determined in a clotting test.7 However,
others have failed to confirm this,9 and it is not known
whether factor XIa is involved. Up till now nothing is known
about whether platelets have any effect in the activation of
factor IX by factor XIa.
Several assays have been described in literature for the
determination of factor IX activation: a coagulation assay in
factor IX-deficient plasma,’#{176}’2 a tritiated activation peptide
release assay,5”#{176}”3 an immunoradiometric assay,” and an
assay in which factor IXa is measured indirectly by deter-
mining the initial rate of factor X activation.’4 The most
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any time during platelet activation. Stirring during platelet
activation was not necessary. These results suggest that
the inhibition is caused by a release reaction. This was
confirmed by centrifugation experiments that showed that
the inhibitory activity could be recovered from the super-
natant of the activated platelets. The inhibitory activity
was destroyed upon boiling and was susceptible to trypsin
digestion. Passage of platelet supernatant over ACA 22
showed that the inhibitory activity eluted with an apparent
molecular weight of less than 1 .200,000 but greater than
669.000. The inhibition of factor Xla was reversible. These
data suggest that platelets release an antiprotease of
factor Xla that reversibly inhibits factor Xla. Lineweaver-
Burk analysis showed that the inhibitor caused both an
increase in Km for factor IX and a decrease in k,,, of factor
IXa formation by factor Xla.
‘B 1986 by Grune & Stratton, Inc.
widespread used is the tritiated activation peptide release
assay,5”#{176}”3 which was originally described for the activation
of factor X by Silverberg et al.’5 In highly purified systems
the appearance of factor IXa procoagulant activity follows
the peptide release by a small lag period.’0 However, in
less-purified systems, other enzymes may be present that
give rise to similar peptide fragments but destroy the proco-
agulant activity of factor IX.6 Therefore, to circumvent
these potential difficulties, we have chosen to use an assay for
factor IX activation by factor XIa, which detects the func-
tional factor IXa activity via its ability to activate bovine
factor X in the presence of phospholipids and CaCl2.’4 To
increase its sensitivity, bovine factor Villa was present. In
that case, however, care has to be taken to add factor VIlla
under rigorously standardized conditions, since the assay is
critically dependent on the amounts of factor Villa present.
This study was undertaken to explore the role of platelets
in factor IX activation by factor XIa. We present evidence
that platelets, upon stimulation, secrete an inhibitor that
interferes with factor IX activation by factor Xla.
MATERIALS AND METHODS
Materials. Chromogenic substrates L-pyroglutamyl-L-prolyl-L-
arginine-p-nitroanilide hydrochloride (S2337) and N-benzoyl-L-
isoleucyl-L-glutamyl-(piperidyl)-glycyl-L-arginine-p-nitroanilide
hydrochloride 52366 were purchased from A.B. Kabi Diagnostica,
Stockholm. The prostacylin analogue ZK 36374 was a kind gift from
Schening AG, Berlin. Plasma deficient in coagulation factors IX, XI,
or XII were from patients congenitally deficient in these factors and
were obtained from George King Biomedical, Overland Park, Kan.
Hormon tendon collagen was obtained from Hormon-Chemi,
Munich. Fatty acid-free human serum albumin and trypsin were
from Sigma Chemical Co. St Louis. Two-milliliter plastic flat-
bottom reaction tubes were obtained from Stenilin Ltd, Teddington,
England; Teflon-coated magnetic stirring bars (7 x 2 mm) were
purchased from Bel-Art Products, Pequannock, Ni. All reagents
used were of the highest grade commercially available.
Proteins. Human factor IX was purified based on a modifica-
tion of the isolation procedure described by di Scipio et al.’7 and the
sulfated dextran column as described by Miletich et al’8 was added.
Citrated fresh-frozen human plasma was thawed, and benzamidine
FACTOR IX ACTIVATION AND PLATELETS 141
(10 mmol/L), hepanin (6 mg/L), and soybean trypsin inhibitor
(10 mg/L) were added. The barium citrate absorption was followed
by ammonium sulfate precipitations (40% and 70% saturation)
before the vitamin K-dependent protein preparation was applied to a
diethyl aminoethyl (DEAE)-Sephadex column followed by a hepa-
nin-Sephadex column.’7 Finally, a sulfated dextran column was used
to purify factor IX.’8 Human factor IXa was prepared from purified
human factor IX as described earlier for bovine factor IXa.’9 Human
factor XI was purified according to Bouma et al.#{176}Human factor
XII was isolated as described by Griffin and Cochrane.2’ fl-Factor
XIIa was prepared from the purified human factor XII as described
by Fujikawa and McMullen.22 Bovine factor X was purified accord-
ing to Fujikawa et al.23 Bovine factor VIlIc was prepared as
described earlier.24 Factor Villa was prepared by activation of factor
V1IIc (1.75 nmol/L) with thrombin (4 nmol/L) for one minute at
37 0C19.24 Bovine thrombin was purified as a prothrombin activation
product as described by Rosing et al.25 The specific activity of the
thrombin preparation was 1 National Institutes of Health (NIH)
U/mL - 1 1 nmol/L when a molecular weight of 35,600 was used for
thrombin. The human factor IX, XI, and XII and the bovine factor
X, and X2 preparations were homogeneous and pure as determined
by gel electrophoresis in the presence of sodium dodecyl sulfate on
10% gels according to Laemmli.26 The specific activities of the
protein preparation as determined with a clotting assay were 193,
211, 74, and 100 U/mg for human factors IX, XI, XII, and bovine
factor X, respectively, assuming one unit of human factor IX, XI,
and XII to be present per milliliter of human normal plasma and one
unit of bovine factor X in one milliliter of bovine normal plasma. All
proteins were stored at - 70 #{176}Cafter dialyzing against the following
buffers: 50 mmol/L Tris-HC1, 175 mmol/L NaCI at pH 7.9 for
human factor IX and bovine factor X; 4 mmol/L sodium citrate, 2
mmol/L acetic acid, 0.15 mol/L NaCI, and 0.5 mmol/L EDTA at
pH 5.0 for human factor XI and XII; and 10 mmol/L morpholino
ethane sulfonic acid, 175 mmol/L NaCl, 10 mmol/L CaCI2, and
10% glycerol at pH 6.5 for bovine factor VIII. Trypsin was insolubil-
ized by coupling trypsin (60 mg) in 0.1 mol/L NaHCO3 to CNBr-
activated Sepharose 4B (3 g) at 4 #{176}Covernight according to the
manufacturer’s instructions.
Preparation of human factor XIa. Human factor XIa was
prepared from human factor XI using human fl-factor XIIa.27 To 10
mL of factor Xl (0.15 mg/mL) in 4 mmol/L sodium acetate, 2
mmol/L acetic acid, 0.15 mol/L NaC1, pH 5.0, was added 1.25 mL
0.5 mol/L Tnis-HC1, 0.15 mol/L NaCI, pH 8.0, at 37 #{176}C.Reaction
was started by adding 1.27 mL fl-factor XIIa (0.59 mg/mL) in 4
mmol/L sodium acetate, 2 mmol/L acetic acid, 0.15 mol/L NaCI at
pH 5.0. Factor XI activation was followed by measuring factor XIa
amidolytic activity. Activation was completed within 90 minutes.
Factor XIa was separated from fl-factor XIIa on a DEAE-Sephadex
column (1.5 x 11.5 cm) at 4#{176}Cin 50 mmol/L Tnis-HC1 and 150
mmol/L NaCl at pH 8.0. Factor XIa did not adhere to the resin,
whereas fl-factor XIIa was eluted by a linear salt gradient (0. 1 to 0.5
mol/L) NaCl.
The amidolytic activity of human factor XIa was measured using
the chromogenic substrate 52366 in a buffer containing 50 mmol/L
Tnis-HC1, I 50 mmol/L NaCI, 20 mmol/L EDTA, and 0.5 mg/mL
human serum albumin, pH 7.9. The kinetic parameters of 52366
hydrolysis by human factor XIa were Km 0.42 mmol/L and k.,,, =
758 s’. L1 was calculated using a concentration offactor XIa based
on a mol wt of 160,000.
Protein concentrations. Determinations of protein concentra-
tions were routinely done according to Bradford.28 Factors IXa, Xa
and thrombin were determined by active-site titration with
p-NPGB-p-nitrophenyl-p’-guanidinobenzoate (p-NPGB) as de-
scnibed earlier’425 Concentrations of factor IX and factor X were
determined by complete activation and subsequent determination of
the active enzyme. Factor Villa concentrations were determined
according to the method ofvan Dieijen et al.24 Factor XIa concentra-
tions were determined from the amount of protein present assuming
a mol wt of 160,000 d.25
Phospholipid vesicles. Phospholipid vesicles were made from a
mixture of 40 mol/100 mL l.2-dioleoyl-sn-glycero-3-phosphosenine
(PS) and 60 mol/l00 mL l.2-dioleolyl-sn-glycero-3-phosphocholine
(PC) in a buffer containing 50 mmol/L Tnis-HCI and 175 mmol/L
NaCI at pH 7.9 as described by Rosing et al.25
Collagen. Collagen was added in the nonfibnillar form, dissolved
in acidic dilution buffer obtained from Hormon-Chemie as described
by Rosing et al.6 The minimal amount ofcollagen inducing aggrega-
tion and secretion was 1 to 2 jzg/mL.
Factor IXa determinations. To follow the activation of factor
IX by factor XIa an assay system was developed in which factor IXa
was determined via its ability to activate bovine factor X in the
presence of CaCI2, phospholipid, and factor VIlla. Factor IXa-
containing samples were diluted in ice-cold buffer containing
50 mmol/L Tnis (pH 7.9), 175 mmol/L NaC1, 0.5 mg/mL human
serum albumin, and 20 mmol/L EDTA to block further activation of
factor IX. The amounts of factor IXa present in the samples were
then determined as follows. Three hundred five microliters buffer
containing 50 mmol/L Tris (pH 7.9), 175 mmol/L NaCI, 9.8
mmol/L CaCI2, 0.5 mg/mL human serum albumin, and 16.4
zmol/L phospholipid vesicles was prewarmed at 37 #{176}Cfor 4’/2
minutes, after which 45 ML bovine factor X (16.67 mol/L) and a
50-L sample were added. Factor X activation was started by adding
l00iL factor Villa (1.75 nmol/L). The final reaction mixture (500
L) contained 50 mmol/L Tnis (pH 7.9), 175 mmol/L NaCI, 6
mmol/L CaCI2, 2 mmol/L EDTA, 10 imol/L phospholipid, 1.5
zmol/L factor X, 0.35 nmol/L factor Villa, 0.5 mg/mL human
serum albumin, and the factor IXa present in the sample. The rate of
factor X activation was determined by measurement of the amounts
of factor Xa formed after one and two minutes in these reaction
mixtures using the factor Xa-specific chromogenic substrate 52337
as described 4J9 From the observed rate of factor X activa-
tion, the amount of factor IXa present in the sample was calculated
using a calibration curve made with known amounts of active-site
titrated factor IXa (see also Fig I).
Kinetic parameters. Km for factor IX and k..,, of factor IX
activation were determined by measurement of the rate of factor IXa
formation in a reaction mixture containing 10 mmol/L CaCI2, 0.5
mg/mL human serum albumin, 0.1 nmol/L factor XIa, and varying
amounts of factor IX in HEPES buffer, pH 7.5, using the assay
previously described. Km and V,,,,, (expressed as factor IXa formed
per second) were then determined by statistical analysis of the data
as described by Eisenthal and Cornish-Bowden. k.,. was calculated
by dividing V,,,,, with the enzyme concentration assuming a mol wt of
160,000 for factor XIa.
Isolation ofhuman platelets. Blood was drawn by venipuncture
from healthy male volunteers who had not taken any medication for
at least ten days. As anticoagulants, 1 vol of acid citrate dextrose
(0. 1 8 mol/L glucose, 0.08 mol/L tnisodium citrate, and 0.052 mol/L
citric acid) was added to 5 vol of whole blood. Platelet-rich plasma
was obtained after centnifugation at 220 g for 25 minutes. Platelets
were isolated by centrifugation at I 000 g for 20 minutes, and the
pellet was gently resuspended in calcium-free HEPES buffer (10
mmol/L HEPES, 136 mmol/L NaCI, 2.68 mmol/L KCI, 2 mmol/L
MgCl2, and 5 mmol/L glucose), pH 6.7, containing 0.4% human
serum albumin. The platelets were washed twice in this buffer by
centnifugation at 600 g for I S minutes. During the whole procedure
except the last wash, acid/citrate/dextrose was present in the buffer
(I vol to 14 vol buffer).3#{176} Finally, the platelets were resuspended in
HEPES buffer, pH 7.5, containing 0.1% human serum albumin.
Platelet concentrations were determined with a Coulter counter
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Fig 1 . Factor IXa calibration curve. The rate of activation of
bovine factor X (1 .5 mol/L) by varying amounts of factor IXa was
determined in the absence (#{149})or in the presence of 3.2 x 107/mL
stimulated platelets (v) or their supernatants (0) at 37 ‘C in a
reaction volume of 500 zL containing 50 mmol/L Tris (pH 7.9). 175
mmol/L NaCI. 6 mmol/L CaCI2. 2 mmol/L EDTA. 10 smol/L
phospholipid vesicles (40% PS/60% PC. mole/mole). 1 .5 mol/L
factor X, 0.35 nmol/L factor VIlla, 0.5 mg/mL human serum
albumin. and amounts of factor IXa as indicated in the figure.
When stimulated platelets or their supernatants were present.
factor IXa was preincubated with the platelets or their superna-
tant for four minutes at 37 ‘C prior to addition to the assay.
Stimulated platelets were prepared by incubation at 37 ‘C for 12
minutes with 1 .2 nmol/L thrombin, 10 g/mL collagen. and 3
mmol/L CaCl2 under continuous stirring. The supernatants were
prepared by centrifuging the stimulated platelets for five minutes
in an Eppendorf microfuge. For experimental details. see Materials
and Methods under Factor IXa determination.
(Coulter Electronics, Luton, England) and were kept at room
temperature.
RESULTS
Validation ofthe assayforfactor IXa. In this study an
assay for the activation of factor IX was used in which
functional factor IXa activity was determined via the activa-
tion of bovine factor X as described earlier.’4 To increase its
sensitivity, the activation of bovine factor X by human factor
IXa was performed in the presence of CaCI2, phospholipids,
and bovine factor VIlla. The amount of factor Xa formed
was linear with time for at least two minutes (data not
shown), and the rates of factor Xa formation were deter-
mined from the amounts of Factor Xa formed during these
two minutes. Figure 1 shows that the rate of factor Xa
formation was proportional to the amount of factor IXa
added (closed circles). The slope of this plot reflects the rate
of factor Xa formation per factor IXa present (59.5 nmol/
Xa/min/nmol IXa). An excellent day-to-day reproducibility
of the calibration curve could be achieved, since four sepa-
rate experiments carried out at different days showed an SD
of 1 .7% in the slope of this plot.
This calibration curve was used in the experiments in
which the activation of factor IX by factor XIa was deter-
mined. Since the experiments presented here concern the
effect of platelets on the activation of factor IX by Factor
XIa, the calibration curve was repeated in the presence of
3.2 x l07/mL thrombin/collagen-stimulated platelets (Fig
I, open triangles) or the supernatant thereof (Fig 1, open
circles). As can be seen, the presence of the triggered
platelets or their supernatants had no effect on the assay for
factor IXa.
Factor IX activation by factor XIa. The assay just
described was used to assess the kinetic parameters of factor
IX activation by factor XIa in the presence of 10 mmol/L
CaCl2. It was verified that factor IX activation was linear
with time and proportional to the amount of factor XIa used
(data not shown). Varying concentrations of factor IX were
incubated with factor XIa, and the rate of factor IXa
formation was determined in the assay just described.
Michaelis-Menten kinetics were observed throughout. The
kinetic parameters were Km 301 nmol/L, and k, = 2.4 s’
assuming a mol wt of 160,000 for factor XIa.
The effect of platelets in the activation of factor IX by
factor XIa was studied. Nonstimulated platelets up to con-
centrations as high as 5 x I08/mL had no effect on factor IX
activation. However, in the presence of platelets stimulated
by the combined action of thrombin and collagen, the rates of
factor IXa formation decreased with time until after two
minutes a low rate of factor IXa formation remained (Fig 2).
Preincubation of factor IX with the activated platelets for
four minutes did not change the time course of factor IX
activation. However, when factor XIa was preincubated with
E
0
E
Fig 2. The effect of platelets in the activation of factor IX by
factor Xla. The activation of factor IX (100 nmol/L) by factor Xla
(0.1 nmol/L) was determined at 37 ‘C in the absence of platelets
(0). in the presence of 5 x 10/mL unstimulated platelets (#{149}).and
in the presence of platelets (5 x 1O/mL) that had been stimulated
for 12 minutes at 37 ‘C under continuous stirring by thrombin (1.2
nmol/L), collagen (10 ig/mL). and 3 mmol/L CaCl (X). The final
reaction mixture contained 10 mmol/L CaCl. 0.5 mg/mI human
serum albumin. 100 nmol/L factor IX. 0.1 nmol/L factor Xla. and 5
x 10/mL platelets in HEPES buffer at pH 7.5. At the time intervals
indicated, samples were withdrawn and assayed for factor IXa as
described in Materials and Methods. The points denoted (A) were
obtained after factor IX was incubated four minutes with the
stimulated platelets prior to the addition of factor Xla. The points
denoted by (#{149})were obtained after a four-minute incubation of
factor Xla with the stimulated platelets prior to the addition of
factor IX.
E
E
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the triggered platelets, only the low rate of factor IXa
formation remained. This strongly suggests that the inhibi-
tion was the result ofa direct interaction with factor XIa that
was completed within four minutes. Subsequent experiments
showed that for platelet concentrations ranging from 106 to
I09/mL a preincubation time with factor XIa of approxi-
mately ten minutes sufficed to result in linear rates of factor
IXa formation. Therefore, in all subsequent experiments,
factor XIa was preincubated for ten minutes with the
platelets prior to the addition of factor IX.
The inhibitory effect of activated platelets at a suboptimal
platelet concentration (4.i07/mL) in factor IX activation by
factor Xla was studied using different platelet agonists
(Table 1). The most potent were thrombin (1.2 nmol/L),
calcium ionophore A 23187 (1 mol/L) and the combined
action of thrombin (1.2 nmol/L) and collagen (10 jzg/mL),
whereas platelets activated by collagen (10 g/mL) or
adrenalin (546 1umol/L) caused a smaller inhibition. Plate-
lets stimulated with adenosine diphosphate (ADP)
(25 imol/L) whether in the absence or presence of fibrino-
gen (0.7 mg/mL), showed no significant inhibition of factor
IX activation by factor XIa under these conditions. Stirring
of the platelets was not necessary to achieve the inhibitory
activity.
Figure 3 shows that factor IX activation was inhibited in a
dose-dependent way. Factor IX formation was not influenced
at platelet concentrations less than 106/mL, and at higher
platelet concentrations inhibition was observed until at a
concentration of4 x 108/mL factor IX activation was almost
completely inhibited. During the platelet activation the lysis
was always smaller than 2%. Lactic dehydrogenase (LDH)
was taken as the parameter for platelet lysis. One hundred
Table 1 . The Effect of Different Platelet Stimulators in Factor IX
Activation by Factor Xl.
Trigger Substance Rate of Factor IX Activation
Notrigger 100%
ADP 95%
ADP/fibrinogen 92%
Adrenalin 84%
Collagen 84%
Thrombin 62%
A23187 58%
Thrombin/collagen 59%
Thrombin/collagen 58%
The platelets were activated by thrombin ( 1 .2 nmol/L) and collagen
( 10 .tg/mL) without stirring.
Platelets (4 x 1 07/mL) were incubated in HEPES buffer (pH 7.5) at
37 ‘C for 12 minutes in the presence of ADP (25 smol/L). ADP (25
zmol/L), human fibrinogen (0.7 mg/mL). a&enalin (546 tmol/L), col-
lagen ( 1 0 zg/mL), onophore A23 1 87 ( 1 .tmol/L), thrombin ( 1 .2 nmol/
L). or thrombin (1.2 nmol/L), and collagen (10 zg/mL). During stimula-
tion the platelets were stirred. After this incubation, factor Xla was added
and incubated for ten minutes with the activated platelet suspension. The
factor IX activation mixture contained 4 x 107/mL platelets, 1 00 nmol/L
factor IX, 0. 1 nmol/L factor XIa. and 10 mmol/L CaCl2 in HEPES buffer,
pH 7.5. Factor IX activation rates were determined as described in
Materials and Methods and expressed as a percentage of the activation
rate measured in the presence of unstimulated platelets (3.58 pmol
lXa/min/mL).
20 30
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Fig 3. Factor IX activation in the presence of varying concen-
trations of activated platelets or their supernatants. Varying
amounts of platelets were stimulated for 1 2 minutes at 37 ‘C
under continuous stirring with thrombin (1 .2 nmol/L) and collagen
10 zg/mL) in the presence of 3 mmol/L CaCI2. The platelets were
then either incubated for an additional five minutes or centrifuged
for five minutes in an Eppendorf Microfuge to obtain the superna-
tant. After this. the CaCI2 concentration was adjusted to 10
mmol/L. and factor Xla was added and incubated for an additional
ten minutes with the platelet suspensions or the supernatants.
Subsequently. factor IX was added. and the rate of factor IXa
formation was determined as described in Materials and Methods.
The final reaction mixtures contained 10 mmol/L CaCI2, 0.5
mg/mL human serum albumin. 100 nmol/L factor IX, and 0.1
nmol/L factor XIa in HEPES buffer (pH 7.5) and amounts of
platelets (#{149})or their supernatants (A) as indicated in the figure.
percent lysis was the amount of LDH measured when the
platelets were sonicated. When the triggered platelet suspen-
sion was centrifuged, all the inhibitory activity was recovered
in the supernatant (Fig 3), indicating that the inhibition is
the result of platelet secretion upon triggering.
The release of inhibition was studied using the prostacy-
din analogue ZK 36374. This substance effectively blocks
any further platelet aggregation3’ and platelet release reac-
tions32 when added to platelet suspensions (Fig 4). The
addition of 100 nmol/L prostacyclin analogue prior to stimu-
lation with 0.2 nmol/L thrombin effectively blocked any
release of inhibitory activity. The time course of release of
inhibitor was determined by the addition of ZK 36374 at
various time intervals after the addition of thrombin to the
platelets. The amounts of inhibitory activity released were
then determined in the supernatant after centrifugation.
Figure 5 shows that secretion of the inhibitor started after a
small lag period of 10 seconds and reached a plateau after a
platelet activation time of approximately four minutes.
Preliminary characterization of the inhibitory activi-
ty. To gain insight into the nature of the inhibitory activity
secreted by platelets, the supernatant of a large amount of
stimulated platelets (1.8 x 1010) was collected, concen-
trated, and passed over a Sepharose ACA 22 column
(2.5 x 85 cm). Figure 6 shows that the inhibitory activity
was included in the column volume but eluted earlier than
the largest mol wt marker available (669,000), thus preclud-
ing an accurate estimation of the apparent mol wt. The
fractions of the column containing inhibitor were pooled and
0123456789
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Fig 4. Influence of ZK 36374 on platelet aggregation and
adenosine triphosphate (ATP) release. Platelet aggregation and
ATP release were measured in an aggregometer. Washed plate-
lets (2.3 x 10/mL) in HEPES buffer containing 2.6 mmol/L CaCl2
and luciferin luciferase reagents were placed in the aggregometer
under stirring conditions. At time 0. platelet activation was started
by adding (0.7 nmol/L. ie 0.06 U/mL) thrombin (open arrow). At
different time points. ZK 36374 (90 nmol/L) was added to stop the
platelet activation (closed arrow). ATP release was monitored by
luciferin-luciferase reaction (A). and platelet aggregation was
measured at the same time (B). When ZK 36374 was added one
minute before thrombin. no ATP release and platelet aggregation
was measured (A, and B, ). When ZK 36374 was added one or
three minutes after thrombin. ATP release and aggregation
stopped immediately (A2. B2. and A3. B3). ATP release and platelet
aggregation were also measured in the absence of ZK 36374 (A
and B4). ATP release is expressed as a percentage. with ATP
release in the absence of ZK 36374 taken as 100%.
concentrated, after which a part was treated with trypsin-
Sepharose. Table 2 shows that no inhibitory activity
remained after this treatment, whereas a control experiment
with only Sepharose showed no loss of inhibitory activity.
When the experiment with the trypsin-treated inhibitor was
repeated in the absence of factor XIa, no activation of factor
IX was observed, indicating that no significant amounts of
trypsin were coming off the beads (data not shown). The
inhibitor was also destroyed when placed in a boiling water
bath for one hour. From these data we conclude that the
inhibitor is a protein or contains a protein part essential for
its activity that is susceptible to trypsin and is heat labile.
The data in Table 3 show that the inhibitor did not destroy
or irreversibly inhibit factor XIa. When factor XIa was
incubated with a high amount of inhibitor, only 21% of the
rate of factor IX activation remained. However, when this
incubation mixture was diluted fivefold, the rate of factor IX
activation was only I .6-fold less. Since rates of factor IX
activation were linear with the amount of factor XIa present
(see also the aforementioned), this indicated that some 50%
of the factor XIa had become available again to participate
Fig 5. Time course of the appearance of inhibitory activity
during platelet activation. Platelets (2.6 x 10/mL) were stimu-
lated at 37 ‘C with thrombin (0.2 nmol/L) in the presence of CaCl2
(3 mmol/L) under continuous stirring. At the time points indicated.
the release reaction was blocked by adding the prostacyclin
analogue ZK 36374 (100 nmol/L). and the platelet suspension was
centrifuged for two minutes in an Eppendorf Microfuge to obtain
the supernatant. After this. the CaCI2 concentration was adjusted
to 10 mmol/L. and factor XIa was added and incubated with the
supernatant for 20 minutes at 37 ‘C. after which factor IX activa-
tion was started with the addition of factor IX. The final activation
mixture contained 10 mmol/L CaCI, 0.5 mg/mI human serum
albumin. 100 nmol/L factor IX. 0.1 nmol/L factor Xla. and superna-
tant of activated platelets (2 x 10/mL) in HEPES buffer. The rate
of factor IX activation in the reaction mixture was determined as
described in Materials and Methods and was expressed as a
percentage of the factor IX activation rate measured in the
presence of unstimulated platelets.
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Fig 6. ACA 22 gel filtration on the supernatant of stimulated
platelets. Platelets (1 .1 5 x 10’/mL) were activated in the pres-
ence of 3 mmol/L CaCl2 with 1 .2 nmol/L thrombin and 10 g/mL
collagen at 37 ‘C for 1 5 minutes in a total volume of 32.5 mL HEPES
buffer (pH 7.5) containing 0.175 mg/mI human serum albumin.
The supernatant was obtained by centrifugation for 20 minutes at
1 5,000 rpm in a Beckman J21 B and subsequently concentrated
eightfold on a PM 10 filter (Amicon. Lexington. Mass). Two
milliliters were applied to an ACA 22 column (2.5 x 85 cm)
equilibrated in HEPES buffer (pH 7.5) at 4 ‘C. Elution was
performed with the same buffer at a flow rate of 40 mL/h. and
fractions of 4.5 ml were collected. Inhibitory activity was deter-
mined by incubating 450 ML of each fraction with 25 L factor Xla
(4nmol/L) for 1 5 minutes at 37 ‘C. after which 25 iL S2366 (5.8
mmol/L) was added and the rate of absorbance change at 405 nm
recorded. The percentage of inhibitory activity was calculated
from the amidolytic activity determined in the absence of inhibitor
taken as 1 00%. Calibration of the column was achieved in a
separate run using dextran blue 2000 (V0). thyroglobulin
(669.000). ferritin (440,000), catalase (232,000). and benzamidine
(V,).
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Table 2. The Effect of Trypsin on the Activity of the Inhibitor in
Factor IX Activation by Factor Xla
Activator
Rate of Factor IX
Activation
(pmol )Xa/min/mL)
FactorXla 3.97
Factor XIa, inhibitor 0.61
Factor Xla, inhibitor after incubation
with Sepharose 4B 0.63
Factor Xla, inhibitor after incubation
with trypsin-Sepharose 4.06
Human factor IX was activated by human factor Xla at 37 ‘C in HEPES
buffer (pH 7.5) containing 100 nmol/L factor IX, 0.1 nmol/L factor Xla,
0.5 mg/mL human serum albumin, and 10 mmol/L CaCI2 in the absence
or presence of inhibitor. The rate of factor IXa formation was determined
as described in Materials and Methods. Factor Xla was preincubated with
inhibitor for 1 5 minutes at 37 ‘C before addition to the reaction mixture.
The effect of trypsin on the inhibitor was determined by incubating 1.0
mL inhibitor with 0.25 mL trypsin-Sepharose slurry (or Sepharose 4B as a
control) at 4 ‘C. After two hours, the suspension was centrifuged and the
supernatant added to factor Xla to determine the residual inhibitory
activity. The inhibitor preparation used was obtained from the ACA-22
column shown in Fig 6. Fractions 48 to 58 of this column contained
inhibitory activity and were pooled. Human serum albumin, 2.5 mg. was
added to the pool (44 mL). which was subsequently concentrated tenfold
before use in the experiment described here.
in factor IX activation. The experiment in Fig 7 also
illustrates this point. Here the time course of the disappear-
ance of factor XIa amidolytic activity towards the chromo-
genic substrate 52366 was followed in an incubation mixture
containing 0.4 nmol/L factor XIa and the supernatant of
2.2 x 108/mL activated platelets (closed squares). After
equilibrium was reached, part of this mixture was diluted
fivefold, and the remaining activity (expressed as a percent-
age of the amount of factor XIa present) was followed with
time (closed circles). As can be seen, the amidolytic activity
increased in the diluted mixture until the same final level was
found as in a mixture that had been diluted fivefold at time 0
Table 3. Effect of Dilution on the Activity of the Inhibitor in
Factor IX Activation by Factor Xla
Rate of Factor lXa Formation
(pmo) )Xa/min/mL)
Activator Before Dilution After Dilution
Factor Xla (0.1 nmol/L) 3.77 0.69
Factor Xla (0. 1 nmol/L), supernatant
of 2 x 108/mL platelets 0.80 0.49
Factor Xla (0. 1 1 nmol/L) was incubated at 37 ‘C in HEPES buffer (pH
7.5) containing 1 mg/mL human serum albumin and 10 mmol/L CaCI2 in
the presence or absence of supernatant from 2.2 x 1 08/mL stimulated
platelets (obtained as described in the legend to Fig 6). After 1 5 minutes.
part of this mixture was diluted fivefold in the same buffer and further
incubated at 37 ‘C for 30 minutes to allow reequilibration of factor Xla
with inhibitor (see legend to Fig 7). After this time interval, factor IX
activation in each of these mixtures was determined by the addition of
factor IX so as to result in a final concentration of 100 nmol/L. Final
concentrations of factor Xla and platelet supernatants reached are
indicated in the table and were fivefold less in the diluted mixtures. The
rate of factor IXa formation was then determined by withdrawing
samples from these reaction mixtures at two and four minutes and
assaying for factor IXa as described in Materials and Methods.
Fig 7. Reversibility of factor Xla inhibition. The supernatant
(7.65 ml) of 2.6 x 10/mL platelets (obtained as described in the
legend to Fig 5 was incubated for five minutes at 37 ‘C. and 0.9 ml
factor Xla (4 nmol/L) was added. Immediately thereafter. 1 .5 ml
was subsampled and diluted fivefold in HEPES buffer containing
0.5 mg/mI human serum albumin. The time course of inhibition in
each reaction mixture was followed by subsampling 475 Ml to a
cuvette at the time intervals indicated in the figure. Twenty-five
microliters of S2366 (5.8 mmol/L) were added. and the rate of
change of absorbance at 405 to 500 nm was determined at 37 ‘C
on a DW2A Spectrophotometer (Amicon, lexington. Mass). As a
control, the amidolytic activity was followed over time in two
reaction mixtures (prepared the same way) without supernatant
present. The final concentrations in each reaction mixture were
0.5 mg/mI human serum albumin in HEPES buffer (pH 7.5); factor
Xla (0.4 nmol/l). no platelet supernatant (0); factor Xla (0.4
nmol/L) and the supernatant of 2.2 x 10/mL platelets (#{149});factor
Xla (0.08 nmol/L). no platelet supernatant (A); and factor Xla
(0.08 nmol/L) and the supernatant of 4.4 x 107/ml platelets (A).
After equilibrium was reached. reversibility of the inhibition was
verified by diluting part of the mixture containing the high concen-
trations of reactants fivefold and following the reappearance of
amidolytic activity (#{149}).The amidolytic activities determined for
each reaction mixture in the presence of platelet supernatant
were expressed as a percentage of the activities determined in the
reaction mixture containing corresponding amounts of factor Xla
but without supernatant present (open symbols).
(closed triangles). Factor XIa activity was stable throughout
the time course of the experiment in both the diluted and
undiluted mixtures in the absence of platelet supernatant
(open symbols). These data indicate that the inhibition of
factor XIa was completely reversible.
Figure 8 shows Lineweaver-Burk plots of factor IX activa-
tion by factor XIa in the presence of varying amounts of
platelet supernatant. These data show that both Vff, and Km
were affected, indicating that the inhibitor is of the mixed
type.
DISCUSSION
In this paper we report the effects of stimulated human
platelets on the activation of human factor IX by factor XIa.
We developed an assay that measures functional factor IXa
via its ability to activate bovine factor X as described
earlier’4 except that apart from phospholipids and CaC12
bovine factor VIlla was also present in the assay. The
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Fig 8. lineweaver-Burk plots of factor IX activation by factor
Xla at various inhibitor concentrations. The kinetic parameters (Km
for factor IX and V,,,,) were determined in the presence of varying
amounts of inhibitor. Variation in the inhibitor concentrations was
obtained by stimulating different platelet concentrations for
twelve minutes at 37 ‘C in the presence of 3 mmol/ I CaCI2 with
thrombin (1 .2 nmol/l) and collagen (10 sg/ml) under continuous
stirring followed by centrifugation for two minutes in an Eppendorf
Microfuge to obtain the supernatants. Subsequently. the CaCI
concentration was adjusted to 1 0 mmol/ I. and factor Xla was
added and incubated for ten minutes at 37 ‘C before the addition of
factor IX. The final reaction mixtures contained 10 mmol/L CaCI2.
0.5 mg/mI human serum albumin. varying amounts of factor IX.
and 0.1 nmol/l factor Xla in HEPES buffer (pH 7.5) without
inhibitor (0) and in the presence of supernatant obtained from 2 x
107/ml platelets (O). 6 x 107/ml platelets (A). and 2 x 10/ml
platelets (s). Rates of factor IX activation were determined as
described in Materials and Methods. and from these. the line-
weaver-Burk plots were constructed. The kinetic parameters
obtained were 14.4 nmol/l factor IXa/min and 0.3 imol/l (0).
10.0 nmol/l factor IXa/min and 0.37 .tmoI/l (#{149}).7.9 nmol/l factor
IXa/min and 0,6 .tmol/L (A). and 3.0 nmol/l factor IXa/min and
0.99 tmol/l (U).
presence of factor VIlla increases the sensitivity some 3,000-
fold but has the disadvantage that for each new batch of
factor VIII a new standard curve must be made. When this is
done, a good day-to-day reproducibility can be achieved, and
the assay allows accurate determination of factor IXa down
to levels of 2.5 pmol/mL (Fig 1 ). Different batches of factor
IXa, factor X, and phospholipid can be used interchangeably
to produce the same standard curve provided equal amounts
of these reagents are used. Using this assay, we determined
the kinetic parameters of factor IX activation by factor XIa,
and we found a Km for factor IX of 0.3 imol/L and a k,,9 of
2.4 s’/factor XIa molecule of 160,000 mol wt. Some
disagreement exists in the literature concerning these kinetic
parameters. Walsh et al’#{176}using factor XIa activated with
bovine factor XIIa found a Km of 0.49 .tmol/L and a k, of
7.7 s-), whereas Bajaj’3 using a trypsin-activated factor XIa
found a km of 2.0 Mmol/L and a k,, of 0.34 s (per 160,000
mol wt factor XIa). Both these studies made use of the
tritiated activation peptide release. The kinetic parameters
determined by us are rather close to the data reported by
Walsh et al.’#{176}
Using this assay, we determined the effect of platelets on
the rate of factor IXa formation by factor XIa. The data
reported here clearly demonstrate that stimulated platelets
cause a dramatic decrease in the rate of factor IX activation
by factor XIa, whereas unstimulated platelets have no effect.
This inhibition is caused by a direct interaction with factor
XIa, since steady-state rates of factor IXa formation can
only be achieved by incubation of factor XIa with the
stimulated platelets, whereas preincubation of factor IX has
no effect (Fig 2). Moreover, factor XIa amidolytic activity
towards the chromogenic substrate 52366 is also inhibited
(see Figs 6 and 7). Various platelet agonists can bring about
this effect, the most potent being thrombin or the ionophore
A23187. The set of agonists that can induce this effect
(Table I ) as well as the rapid time course of the appearance
of inhibitory activity after stimulation of the platelets (Fig 5)
suggests the involvement of a release reaction. This is in
accordance with the finding that the inhibitory activity is
quantitatively recovered in the supernatant after centrifuga-
tion in a microfuge for five minutes (Fig 3). The amount of
inhibitory activity is dependent on the amounts of stimulated
platelets present. Thus, under the conditions used in our
experiments, factor IX activation is not affected by the
presence of 106/mL platelets. At the physiologic platelet
concentration (2 x 108/mL), about 10% of the factor IX
activation rate is left. Thus, the inhibitory activity reported
here may play a role under physiologic circumstances. How-
ever, more experiments will be needed to gain insight into
this.
The high apparent mol wt with which the inhibitor elutes
from an ACA 22 column as well as the rather broad elution
profile (see Fig 6) suggests that the inhibitor consists or is
part of high-mol wt complexes. This may indicate that the
inhibitor is associated with the so-called platelet dust.33
However, an essential part of the large inhibitor molecules
eluting from the ACA 22 column must be proteinlike in
nature, since the inhibitory activity was completely destroyed
after tryptic digestion. Moreover, the activity is also
destroyed upon boiling. Therefore, at this moment we work
under the hypothesis that the inhibitory activity is due to a
protein that is released. This is most likely an antiprotease
that reversibly blocks the factor XIa active sites both for
factor IX activation and for S2366 conversion, since the
inhibition seems reversible (see Table 3 and Fig 6). This
inhibition is of the mixed type as determined by Lineweaver-
Burk analysis of factor IX activation by factor XIa in the
presence ofvarying amounts of inhibitor (Fig 8).
The main plasma inhibitors of factor XIa are a1-antitryp-
sin and antithrombin III. a,-Antitrypsin is also present in
platelets and can be secreted upon stimulation.35 However,
these inhibitors have a much lower molecular weight and
irreversibly block factor XIa. Therefore, our data do not
suggest any involvement of these proteins in the inhibition
that we observe in our experiments. At this moment we do
not know whether under different experimental conditions
the cr1-antitrypsin present in platelets may become involved
in the inhibition of factor IX activation by factor XIa.
It has been suggested that high-mol wt kininogen
(HMWK) protects factor XIa against inactivation by
plasma inhibitors,34 and a recent report of Schmaier et al
shows that HMWK can be secreted from human platelets
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upon stimulation.36 The results presented here show that
despite these amounts of HMWK present in the platelets the
rate of factor IX activation by factor XIa decreases in the
presence of stimulated platelets. Sinha et al have recently
presented evidence that factor XIa needs HMWK to bind to
stimulated platelets and that the amount of HMWK secreted
by platelets is not sufficient to cause measureable factor XIa
binding to triggered platelets.37 Therefore, it will be impor-
tant to investigate whether factor XIa binding via HMWK to
stimulated platelets can prevent the inhibition of factor IXa
formation caused by stimulated platelets in the absence of
external HMWK.
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